# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ATA3219 Demonstrates Complete CD19-Specific B-Cell Depletion Against Systemic Lupus Erythematosus and Multiple Sclerosis Patien...
HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) with a Neutral.
First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug AdministrationIf Approved, Tab-cel Would be First Approved...
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of...